The prognostic value of CXCR4 in acute myeloid leukemia

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 1, 2013, Pages 79-84

  Ahn, Jeong Yeal ^a,b   Seo, Katie ^a   Weinberg, Olga K ^a,c   Arber, Daniel A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Gachon University College of Medicine   (South Korea)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

acute myeloid leukemia; CXCR4; normal karyotype; prognostic factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DISEASE COURSE; FEMALE; GENE MUTATION; HEREDITY; HUMAN; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CXCR4; RISK; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871982472     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182606f4d     Document Type: Article

References (17)

1. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-a (C/EBPa), in acute myeloid leukemia. Nat Genet. 2001;27:263-270. (Pubitemid 32201846)
2. Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372-4380. (Pubitemid 35434129)
3. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2010;28:2348-2355.
4. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266. (Pubitemid 40110814)
5. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:237-251. (Pubitemid 36667562)
6. Konoplev S, Rassidakis GZ, Estey E, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007;109:1152-1156. (Pubitemid 46435395)
7. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113: 6215-6224.
8. Nervi B, Ramirez P, Retting MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206-6214.
9. Burger JA, Burkle A. The CXCR4 chemokine receptor in acute and chronic leukemia: a marrow homing receptor and potential therapeutic target. BJH. 2007;137:288-296. (Pubitemid 46650259)
10. Tavernier-Tardy E, Cornillon J, Campis L, et al. Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res. 2009;33:764-768.
11. Spoo AC, Lubbert M, Wierda WG, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood. 2007;109:786-791. (Pubitemid 46105982)
12. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113: 1906-1908.
13. Shin LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100:2387-2392.
14. Ahn JY, Seo K, Weinberg O, et al. A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. J Mol Diagn. 2009;11:319-323.
15. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004;64:2817-2824. (Pubitemid 38500620)
16. Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. BJH. 2001;115: 545-553. (Pubitemid 34015643)
17. Zhang W, Navenot JM, Frilot NM, et al. Association of nucelophosmin negatively regulates CXCR4-mediated G protein activation and chemotaxis. Mol Pharmacol. 2007;72:1310-1321. (Pubitemid 350012604)